Recent Publications

AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma. Phase 1a study explored the safety, tolerability, and pharmacokinetics of our compound, which is promising new medication for chronic stable angina. Now that the meeting’s embargo has lifted, we are thrilled to share these results with you! Check out the attached presentation for more details.If you would like the full version of the deck, feel free to reach out directly to Uwe Tigör, MD or Jed Litwiniuk.

About chronic stable angina

Chronic stable angina pectoris is a type of angina that is characterised by recurring chest pain or discomfort. It occurs when there is reduced blood flow to the heart muscle due to narrowed or blocked coronary arteries. The chest pain in chronic stable angina is usually triggered by physical exertion or emotional stress and typically lasts for a few minutes.

GlobalData estimates that sales of the angina market (stable, microvascular, variant) to be approximately $7.8bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) in 2028. GlobalData is the parent company of the Clinical Trials Arena.

About Auxilius Pharma

Auxilius Pharma is a privately held pharmaceutical company that commenced operations in 2019. Auxilius operates in the space of value-added medicines and brings innovation to areas of high unmet need for patients with diseases such as chronic stable angina pectoris that aim to impact public health positively. Auxilius Pharma’s R&D Strategy is driven by patients' need for affordable medications to manage their chronic conditions in the US and on other major markets.